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Progressive supranuclear palsy (PSP) was originally described in 1964. Although some
contended it was merely a variant ofParkinson's disease, a specific electron microscopic finding of
straight, rather than twisted, filaments in the neurofibrillary tangles established PSP as a distinct
entity. The almost pathognomonic early clinical finding of paralysis of downward gaze is due to
lesions involving the lateral portions of the rostral interstitial nucleus of the medial longitudinal
fasciculus. Recent neurochemical studies have identified both a decrease in central dopamine and
acetylcholine. The etiology ofPSP is unknown, and the therapy is generally ineffective.
"It looks like afunny kind ofparkinsonism."
Professor Gilbert H. Glaser, 1963
While a neurology resident in New Haven Hospital in 1963, I presented a demented
patient who carried a diagnosis ofParkinson's disease but was unable to move his eyes.
He had no tremor and his neck wasquiterigid. After examining thepatient, Dr. Glaser
made the comment quoted above but was puzzled about the actual diagnosis. Steele,
Richardson, and Olszewski (S-R-O) "named" and first fully described progressive
supranuclear palsy (PSP) clinically and pathologically in the April 1964 issue of the
Archives ofNeurology [1]. Since then, I haveclosely followed the literature odyssey of
this curious malady and made some minor contributions to its phenomenology. A
personalized review follows.
The subtitle of the S-R-O paper described "a heterogenous degeneration involving
the brainstem, basal ganglia and cerebellum with vertical gaze and pseudobulbar
palsy, nuchal dystonia and dementia." It seemed like a "new" disease, and I was
pleased to have seen a case previously. At the time of the publication, I discussed the
syndrome with Dr. Noble David of Miami, who was following several cases. Doctor
David later published the first good description ofthe eye movement abnormality [2]
which he had presented previously at the 1967 American Academy of Neurology
meetings in San Francisco [3]. The discussant, Dr. Morris Bender, doubted that PSP
was a separate disease and criticized David's pathophysiological explanation ofthe eye
movement abnormality. Bender contended that these patients merely had Parkinson's
disease with rigidity oftheir extraocular muscles.
In 1969, we gave L-dopa (then an experimental drug) to two patients with PSP [4].
One ofthese patients did not respond, but the generalized rigidity and bradykinesia of
the other definitely improved; the ophthalmoparesis did not change. This seemed to
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strengthen David's position that the eye signs were more than simple parkinsonian
rigidity. A report soon followed, describing correction of the ophthalmoparesis with
L-dopa [5]. However, the patient had a major tremor which made PSP a tenuous
diagnosis. In a 1980 review of 75 pathologically verified and 310 clinical cases, only
nine clinical and one anatomical case had tremor [6]. A more extensive experience
with L-dopa found an improvement in one-third, but there was no improvement in the
eye movements [7]. When I read the infrequent report of the eyes improving with
treatment in PSP, I become skeptical of the diagnosis and/or the observation
(admittedly for what might represent no more than an old bias). Although dopamine
agonists (bromocriptine and pergolide) are reported occasionally to be effective [8], it
usuallydoes notsignificantly improve a patient's functional performance for more than
several months.
We performed the first quantitative oculographic analysis in PSP [9]. A surprising
finding, which we did not appreciate clinically, was square-wave jerks (SWJ), a sign
then regarded as somewhat specific for cerebellar dysfunction. It is now recognized
that excessive SWJ, the most common saccadic intrusion [10], occurs in almost all
central nervous system diseases including Parkinson's, schizophrenia [11], affective
disorders [12], and unaffected relatives ofschizophrenics [13].
The concept ofPSP as a distinct diagnostic entity remained challenged, particularly
by Bender's group [14]. Dr. Stanley Fahn classified it as "Parkinsonism Plus" [15]
(coined from "ophthalmoplegia plus," another condition in which we have an
avuncular interest). Fahn used the term generically to categorize syndromes which
manifest, in addition to other clinical signs, features of parkinsonism. We used it as a
hedge: "Although the typical clinical and pathological findings in PSP distinguish the
complete form of this disease from Parkinson's, there occasionally are patients with
seemingly typical Parkinson's (except for the tremor) who have the gaze disturbance
suggestive of PSP. Such patients may be best described as 'parkinsonism plus' " [16].
The neurofibrillary tangles in PSP are non-specific, as originally discussed by
S-R-O. However, the fine structure of these tangles has a unique characteristic; they
are straight rather than "twisted." This observation was originally described in 1973
[17], and it has been verified by others [18]. These tangles show positive immunolabel-
ing with antisera against a purified human brain microtubule fraction that also binds
specifically to the tangles of Alzheimer's disease but not Parkinson's disease or
striatonigral degeneration [19]. Before his death, Dr. Bender accepted PSP as being
different from Parkinson's disease [20].
Since supranuclear ophthalmoplegias usually spare downward gaze [21], the
characteristicdowngaze palsy ofPSP is intriguing. The extensive pathology prevented
pathologic correlation, but the opportunity arose when a case of isolated downgaze
palsy was presented by Dr. Larry Jacobs at the 1972 meeting of the American
Neurological Association [22]. The lesion was superior and medial to the red nuclei
bilaterally and the single previous case had a similar lesion. All pathologically proven
cases of PSP demonstrating downgaze palsy had identically situated lesions [23].
Buttner-Ennever and colleagues [24] later identified the critical structure as the
rostral interstitial nucleus of the medial longitudinal fasciculus, the lateral portions of
which have neurons concerned primarily with downward eye movements. It is now
evident that patients with PSP may not have ophthalmoparesis or it may be delayed
[25-27]. These were some of the patients constituting the "border zone" between
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Parkinson's and PSP which prompted us to embrace "parkinsonism plus." The
indeterminate cases can now be safely designated as PSP.
The dementia in PSP has attracted considerable attention. Although regarded as a
subcortical dementia [28,29], with a bradyphrenia and only a mild dementia [30],
many cases do have significant cognitive impairment [27,31,32]. The concept of
"subcortical dementia" is quite misleading [33] and should probably be abandoned.
The November 1985 issue of the Annals ofNeurology included two reviews of the
neurochemical abnormalities of PSP [32,34], preceded by an excellent summarizing
editorial [35]. There is decreased dopamine concentration in the striatum, but not to
the degree found in Parkinson's, and only a 20 percent decrease ofcholine acetyltrans-
ferase in the cerebral cortex. The latter was said to support a "subcortical" etiology for
the dementia. Loss ofcholinergic interneurons in the basal ganglia might explain both
the lack of tremor and the relative ineffectiveness of dominergic or anticholinergic
drugs in PSP. Whereas in Parkinson's disease there is an imbalance between dopamine
and acetylcholine (the former being relatively decreased and the latter relatively
increased), in PSP they both are decreased, preserving the balance.
For those who want a current review of PSP, I recommend Kristensen's [36]. The
etiology of PSP is unknown, and the therapy remains generally ineffective. However,
the clinical phenomenology, neuropathology, and neurochemical pathology is becom-
ing better defined in this "funny kind ofparkinsonism."
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